crrt的规范化治疗.pptVIP

CRRT的规范化治疗 ;概述;CRRT;历史;主要技术;总 结;急性肾损伤;RIFLE Criteria for Acute Renal Dysfunction;“Acute on Chronic” Disease;AKIN分层标准;适应症;肾脏疾病;Acute renal failure;非肾脏疾病;禁忌症;Potential indications for CRRT in the ICU;Potential indications for CRRT in the ICU;治疗前患者评估;CRRT现状调查;CRRT现状调查;Age (years) 66 (51–74) Reasons to start CRRT Gender (male) 662/1006 (65.8%) Oliguria/anuria 703/1002 (70.2%) Premorbid renal function High urea/creatinine 531/1002 (53.0%) Normal 590/1006 (58.6%) Metabolic acidosis 437/1002 (43.6%) Chronic impairment 283/1006 (28.1%) Fluid overload 368/1002 (36.7%) Unknown 133/1006 (13.2%) Hyperkalemia 186/1002 (18.6%) SAPS II 48 (39–62) Immunomodulation 136/1002 (13.6%) Predicted mortality (%) 41.5 (23.0–71.4) Others 70/1002 ( 7.0%) Hospital to ICU (days) 1 (0–7) ICU mortality 555/1003 (55.3%) ICU to start (days) 1.2 (0.4–4.1) Hospital mortality 641/ 999 (64.2%) Contributing factors to ARF SMR 1.38 (1.28–1.50) Sepsis/septic shock 504/1003 (50.2%) Major surgery 377/1003 (37.6%) Low cardiac output 262/1003 (26.1%) Hypovolemia 201/1003 (20.0%) Drug induced 176/1003 (17.5%) Hepatorenal syndrome 73/1003 (7.3%) Obstructive uropathy 20/1003 (2.0%) Others 114/1003 (11.4%);CRRT mode Anticoagulation CVVH 531/1006 (52.8%) Unfractionated heparin 429/1000 (42.9%) CVVHDF 342/1006 (34.0%) Sodium citrate 99/1000 (9.9%) CVVHD 132/1006 (1